Report - (TSGH Pharmacy Newsletter) · 癌病患有顯著的療效或生存期效益。 目前，FDA 未考慮將Iressa®（gefitinib）從市場中撤回 。新的臨床試驗仍在進行中，俟該試驗完

Select PornographicDefamatoryIllegal/UnlawfulSpamOther Terms Of Service ViolationFile a copyright complaint

Please pass captcha verification before submit form